Raj Satkunasivam
Urology · Houston, TXNPI 1134551278
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.6%), education and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Intuitive Surgical at 45.1% of the total. 2025 is the largest year on record at $9,253, more than ten times the $266 reported in 2019.
Across 112 payments — averaging $250.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$13K
- Ferring Pharmaceuticals Inc.$6K
- Pfizer$5K
- AstraZeneca$3K
- Angiodynamics, Inc.$451
- Boston Scientific$446
- plus $1K from 26 others
Across 180 payments — averaging $14,038 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.2M
- Pfizer$531K
- Janssen Research & Development, LLC$393K
- E.r. Squibb & Sons, L.L.C.$184K
- Urogen Pharma, Inc.$150K
- QED Therapeutics, Inc.$44K
- plus $35K from 1 others
What the payments were for
- Consulting fees$10,56738%
- Speaking & faculty fees$1,5005%
- Travel & lodging$3,66213%
- Food & beverage$2,83410%
- Education$9,51434%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $12,662 |
| Ferring Pharmaceuticals Inc. | 17 | $5,571 |
| Pfizer | 8 | $4,553 |
| AstraZeneca | 2 | $3,222 |
| Angiodynamics, Inc. | 2 | $451 |
| Boston Scientific | 9 | $446 |
| Urogen Pharma, Inc. | 9 | $180 |
| Astellas Pharma US Inc | 7 | $116 |
| Convatec Inc. | 4 | $88 |
| 180 Medical, Inc. | 4 | $85 |
| Baxter Healthcare | 2 | $81 |
| Tempus AI, Inc | 1 | $75 |
| AbbVie | 3 | $56 |
| Myovant Sciences Inc. | 3 | $56 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Myriad Genetic Laboratories, Inc. | 2 | $36 |
| Abbott | 1 | $34 |
| Rochester Medical Corporation | 2 | $31 |
| Procept Biorobotics Corporation | 1 | $26 |
| Endo Pharmaceuticals Inc. | 2 | $26 |
| Laborie Medical Technologies Corp. | 2 | $25 |
| Axonics, Inc. | 1 | $25 |
| ABC Home Medical Supply, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Ambu Inc. | 1 | $22 |
| Alafair Biosciences, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $21 |
| Verity Pharmaceuticals Inc. | 1 | $20 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$11,145
- ADSTILADRIN$5,193
- BAVENCIO$1,750
- DA VINCI SP$1,500
- Nanoknife$428
- AMS 700 CXR RTE KIT$126
- GENERAL KIDNEY STONE DISEASE$118
How this compares
$28,076 in reported general payments places this provider in the 85th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Docetaxel | 23 | $25,263 |
| Gemcitabine Hcl | 26 | $3,576 |
| Tamsulosin Hcl | 134 | $2,129 |
| Finasteride | 30 | $440 |
| Ciprofloxacin Hcl | 62 | $254 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 16 | $204 |
| Sodium Chloride0.9 % Sodium Chloride | 14 | $188 |
| Tramadol Hcl | 49 | $70 |
| Amlodipine Besylate | 12 | $3 |
| Metformin Hcl ErMetformin Hcl | 11 | $0 |
Paid to pharmacies, not to this prescriber.
Other urology in Houston
- Arun RaiHouston$920K
- Donald GriffithHouston$732K
- Jonathan Clavell HernandezHouston$500K
- Ashish KamatHouston$481K
- Mohit KheraHouston$428K
- Ricardo GonzalezHouston$314K
- Richard LinkHouston$261K
- Steven CanfieldHouston$256K
- Run WangHouston$195K
- Kathleen KobashiHouston$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.